

## Ten Most Popular *EJC* Papers

The *EJC* is published in print and online via ScienceDirect (www.sciencedirect.com). ScienceDirect offers access to content from the *EJC* to thousands of researchers around the world, disseminating the work of our authors to its international community within the field of oncology and beyond. We aim to let you know on a quarterly basis which papers from the journal have proved the most popular within ScienceDirect in the preceding months. Please find the top 10 papers from the most recent quarter listed below, which we hope you find of interest.

	Title	Author(s)	Citation
1	The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications	Burger AM, Seth AK	<i>Eur J Cancer</i> 2004, <b>40</b> , 2217–2229
2	Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment	Jordan K, Kasper C, Schmoll H-J	<i>Eur J Cancer</i> 2005, <b>41</b> , 199–205
3	Gene expression microarray technologies in the development of new therapeutic agents	Clarke PA, Poele Rt, Workman P	<i>Eur J Cancer</i> 2004, <b>40</b> , 2560–2591
4	The choice of systemic adjuvant therapy in receptor-positive early breast cancer	Dellapasqua S, Castiglione-Gertsch, M	<i>Eur J Cancer</i> 2005, <b>41</b> , 357–364
5	Endocrine treatment options for advanced breast cancer – the role of fulvestrant	Robertson JFR, Come SE, Jones SE, Beex L, Kaufman M, Makris A, Nortier JWR, Possinger K, Rutqvist L-E	<i>Eur J Cancer</i> 2005, <b>41</b> , 346–356
6	Genomic and proteomic technologies for individualisation and improvement of cancer treatment	Wulfkuhle J, Espina V, Liotta L, Petricoin E	<i>Eur J Cancer</i> 2004, <b>40</b> , 2623–2632
7	Intracellular signalling and cancer: complex pathways lead to multiple targets	Bell HS, Ryan KM	<i>Eur J Cancer</i> 2004, <b>41</b> , 206–215
8	Biomarkers of ovarian tumours	Rapkiewicz AV, Espina V, Petricoin EF, Liotta LA	<i>Eur J Cancer</i> 2004, <b>40</b> , 2604–2612
9	Diagnostic and therapeutic management of cancer of an unknown primary	Pavlidis N, Briasoulis E, Hainsworth J, Greco FA	<i>Eur J Cancer</i> 2003, <b>39</b> , 1990–2005
10	How to develop a successful cancer drug – molecules to medicines or targets to treatments?	Newell DR	<i>Eur J Cancer</i> 2005, <b>41</b> , 676–682